Palisade Bio (PALI) announced it has appointed Emil Chuang to its Board of Directors. Chuang is a pediatric gastroenterologist with nearly 25 years of pharmaceutical and clinical experience spanning large pharma, biotech, therapeutics, medical nutrition, and diagnostics. His expertise spans from preclinical translational medicine through Phase 1-4 clinical development. Notably, his leadership has contributed to multiple drug development programs, including two successful regulatory approvals: infliximab for pediatric Crohn’s disease and lorcaserin for morbid obesity. Following a successful academic career as an Assistant Professor at both Duke University and the University of Pennsylvania, Dr. Chuang transitioned into the pharmaceutical industry, where he has earned a reputation for simplifying complex challenges into actionable development strategies. His work includes significant contributions to programs targeting inflammatory bowel diseases, including infliximab and vedolizumab.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI:
- Palisade Bio Reports Improved Quarterly Losses
- Buy Rating for Palisade Bio: Promising Phase 1a Trial Results and Strategic Focus on Unmet Needs in Crohn’s Disease
- Palisade Bio files to sell 13.14M shares of common stock, warrants
- Palisade Bio reports Phase 1a results for PALI-2108
- Palisade Bio’s PALI-2108: Promising Phase 1 Results and Strategic Positioning Drive Buy Rating